[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"age-related-lung-function-decline\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:age-related-lung-function-decline":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":5},"100644840","phase-2-ongoing-lung-decline-with-age-intensified-response-100644840",false,"NCT07676435","Ongoing Lung Decline With Age Intensified Response","A PHASE II, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE ONGOING LUNG DECLINE WITH AGE INTENSIFIED RESPONSE (OLD AIR)","OLD AIR","Inclusion Criteria:\n\n* Adults aged 60 years and older who are physically capable of participating in study procedures;\n* Willing to be randomized to fisetin or placebo; weight stable within the previous 2 months (\\\u003C5-pound change);\n* No blood donation within 2 months before screening; absence of unstable chronic disease;\n* Willing to maintain baseline activity level throughout the study;\n* Body mass index \\\u003C30 kg\u002Fm²;\n* Either a history of at least 10 pack-years of cigarette smoking or never-smoking status.\n\nExclusion Criteria:\n\n* Electrocardiogram (ECG) abnormalities, including prolonged QTc.\n* Use of fisetin, other flavonoid supplements, or known senolytic compounds within 6 months prior to screening.\n* Resting systolic blood pressure \\>160 mmHg or diastolic blood pressure \\>110 mmHg.\n* Known allergy or hypersensitivity to fisetin or any component of the study product.\n* Active malignancy, except non-melanoma skin cancer.\n* Clinically significant hepatic, renal, cardiovascular, endocrine, immunologic, metabolic, or other uncontrolled medical conditions that, in the opinion of the investigator, would interfere with study participation or interpretation of results.\n* Clinically significant laboratory abnormalities, including severe anemia, leukopenia, thrombocytopenia, uncontrolled diabetes, advanced kidney disease, significant liver dysfunction, or evidence of systemic inflammation.\n* Human immunodeficiency virus (HIV) infection, active hepatitis B or hepatitis C infection, or invasive fungal infection.\n* History of diverticulitis or diverticulosis with gastrointestinal bleeding.\n* Current use of systemic corticosteroids.\n* Current use of warfarin.\n* Current use of medications with significant interaction potential with fisetin, including selected CYP450 or transporter substrates, inhibitors, or inducers, unless such medications can be safely withheld according to protocol requirements.\n* Recent medication, supplement, or lifestyle changes that may affect study outcomes, in the opinion of the investigator.\n* Inability to perform required study procedures, including pulmonary function testing, exercise testing, or other protocol assessments.\n* Unwillingness or inability to provide informed consent.\n* Pregnancy or breastfeeding.\n* Any other condition that, in the opinion of the investigator, would make participation unsafe or compromise study integrity.",true,"ALL","60 Years",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This Phase II, randomized, double-blind, placebo-controlled pilot study will evaluate the effects of fisetin, a senolytic flavonoid compound, on lung function and biomarkers of cellular senescence in older adults aged 60 years and older. Participants will include individuals with a history of at least 10 pack-years of smoking as well as age-matched never-smokers. Forty participants will be randomized to receive either fisetin or placebo using a short-course \"hit-and-run\" dosing strategy (approximately 20 mg\u002Fkg\u002Fday orally for 2 consecutive days on Days 1-2 and Days 8-9).",[28],"Age-Related Lung Function Decline",[30,31,32,33,34,35],"Aging","Cellular Senescence","Healthy Aging","Smoking-Related Lung Function Decline","Pulmonary Function","Smoking","RECRUITING","2026-06-30",{"date":39,"type":40},"2026-07-01","ACTUAL",{"date":42,"type":40},"2026-06-17",{"date":44,"type":22},"2027-07-15",{"name":46,"class":47},"Cedars-Sinai Medical Center","OTHER"]